Most HPV infections clear on their own without any treatment. About 70% resolve within one year, and 90% within two years, with the immune system eliminating the virus entirely. But the remaining cases, where the infection persists, are where the real risks begin. What happens next depends on the HPV type, your immune health, and how long the infection lingers.
Most Infections Clear Without Treatment
HPV is extremely common, and the body handles it well in the vast majority of cases. Your immune system recognizes and eliminates the virus the same way it fights off other infections. There is no antiviral medication that targets HPV directly, so even when doctors diagnose it, the standard approach for a straightforward infection without visible warts or abnormal cells is simply monitoring over time.
This is why many people never know they had HPV at all. The infection comes and goes silently, often within months. The concern isn’t with these self-resolving infections. It’s with the roughly 10% that stick around past the two-year mark, because persistent HPV is the gateway to every serious complication.
What Persistent High-Risk HPV Does to Cells
There are over 200 types of HPV, but only about a dozen are classified as “high-risk” because they can cause cancer. HPV types 16 and 18 are responsible for roughly 76% of cervical cancers. When these high-risk types persist, they gradually alter the DNA of the cells they infect, pushing them toward uncontrolled growth.
This doesn’t happen quickly. It typically takes 5 to 10 years for HPV-infected cervical cells to become precancerous, and around 20 years to develop into invasive cancer. That long timeline is actually good news, because it means there are many opportunities to catch and address changes before they become dangerous. But if no one is looking, those changes can progress unchecked.
How Precancerous Lesions Progress
Precancerous cervical changes are graded by severity. The mildest form (CIN 1) regresses on its own about 60% of the time. Another 25% of cases simply persist without getting worse, and only about 11% progress to more advanced precancerous stages. Less than 1% of women with CIN 1 develop cervical cancer.
Moderate changes (CIN 2) still regress in roughly 55% of cases, but about 19% progress to something more serious. The most advanced precancerous stage (CIN 3) is different. Only 28% of CIN 3 cases regress naturally, while 67% persist. At this stage, the cells are one step away from invasive cancer, and treatment becomes important.
The key takeaway: mild abnormalities often resolve, but each step up the ladder makes spontaneous resolution less likely and intervention more necessary. Without screening to catch these changes, you wouldn’t know what stage you’re in until symptoms appear, which usually means cancer has already developed.
Cervical Cancer Is the Biggest Risk
Almost all cervical cancers, roughly 95%, are caused by persistent HPV infection. Globally, it remains one of the leading causes of cancer death in women, particularly in countries where screening and vaccination rates are low. The disease is almost entirely preventable with regular Pap tests or HPV tests, which detect precancerous changes years before cancer develops.
Without those screenings, cervical cancer typically doesn’t produce noticeable symptoms until it has advanced. By then, treatment is more complex and outcomes are worse. This is the central danger of leaving HPV unchecked: not the virus itself, but the silent cellular changes it can cause over many years.
Cancers Beyond the Cervix
HPV doesn’t only affect the cervix. Persistent infection can cause cancers in several other parts of the body, and these are harder to screen for.
Throat cancer is one of the most significant. HPV causes an estimated 60% to 70% of oropharyngeal cancers in the United States, which affect the base of the tongue, tonsils, and back of the throat. These cancers are more common in men and can take years to develop after infection. Symptoms include a persistent sore throat, difficulty swallowing, earaches, hoarseness, swollen lymph nodes, and unexplained weight loss. There is no routine screening test for HPV-related throat cancer, so it’s typically caught only after symptoms appear.
Anal cancer is strongly linked to HPV as well. About 8,300 people are diagnosed with anal cancer each year in the U.S., and roughly 91% of those cases are attributed to HPV. Penile cancer is rarer, with about 1,400 cases per year, but 63% are HPV-related. HPV also causes a significant portion of vaginal and vulvar cancers.
What Happens With Genital Warts
Low-risk HPV types (mainly types 6 and 11) cause genital warts rather than cancer. If left untreated, warts can follow one of three paths: they may disappear on their own, stay the same, or grow larger and multiply. There’s no way to predict which outcome you’ll get.
Warts that grow can become uncomfortable and harder to treat later. They’re also contagious. HPV can be passed to sexual partners even when no visible warts are present, and the virus can still be transmitted after warts have resolved. Treatment doesn’t eliminate the virus, but it does remove the visible growths and may reduce (though not eliminate) the chance of passing them on.
Why Some People Can’t Clear the Virus
Your immune system is the primary factor determining whether HPV persists or resolves. Several conditions make clearance harder and progression to cancer more likely.
HIV is the most significant co-factor. People living with HIV have weakened immune defenses, particularly when their CD4+ T cell counts drop below 200. These T cells are critical for recognizing and destroying HPV-infected cells. Without enough of them, the body can’t mount an effective response, and HPV infections are more likely to persist, resist treatment, and progress to high-grade precancerous lesions or cancer.
Organ transplant recipients and others taking immunosuppressive medications face similar risks. Their deliberately suppressed immune systems can’t fight HPV as effectively, leading to more persistent and aggressive disease.
Smoking also plays a role. Tobacco use is significantly associated with the progression of high-risk HPV to precancerous changes and cancers of the cervix, throat, anus, and penis. Chemicals in tobacco appear to enhance the activity of HPV’s cancer-causing genes in infected tissue. If you have a persistent HPV infection, smoking makes a bad situation worse.
Monitoring Versus Treatment
Because most HPV infections resolve and there’s no antiviral drug for the virus itself, doctors don’t treat HPV directly. Treatment targets the problems HPV causes: warts are removed, and precancerous cells are treated before they can become cancer. The virus itself may or may not clear after these interventions.
For people with a positive HPV test but no abnormal cells, the standard approach is repeat testing at regular intervals to watch for changes. This isn’t neglect. It’s a recognition that the immune system handles most infections, and intervening too early can mean unnecessary procedures. The shift to active treatment happens when screening detects precancerous changes, particularly moderate or severe ones that are less likely to resolve on their own.
The real risk of “not treating HPV” isn’t skipping a medication that doesn’t exist. It’s skipping the screening that catches problems early. A persistent HPV infection with regular monitoring is a manageable situation. A persistent infection that no one is watching is how preventable cancers develop over 10 to 20 years without anyone noticing until it’s too late.